2271392-87-9

Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-methyl-1,2,3,5,6,7-hexahydro-s-indacen-4-amine is used as a potential pharmaceutical compound for its unique molecular and stereochemical properties. (S)-3-methyl-1,2,3,5,6,7-hexahydro-s-indacen-4-amine's amine functionality and chirality may offer advantages in the development of new drugs, targeting specific biological receptors or pathways.
Used in Organic Synthesis:
In the field of organic synthesis, (S)-3-methyl-1,2,3,5,6,7-hexahydro-s-indacen-4-amine can be utilized as a building block or intermediate for the creation of more complex molecules. Its amine group and cyclic structure provide opportunities for further chemical modifications and the synthesis of novel compounds with tailored properties.
Used in Industrial Applications:
(S)-3-methyl-1,2,3,5,6,7-hexahydro-s-indacen-4-amine may also find use in various industrial applications, such as in the development of new materials or chemical processes. Its unique structure and properties could be harnessed to improve existing technologies or create new ones, pending further investigation into its potential.

Upstream product

• 39105-39-0 3-chloro-1-(2,3-dihydro-1H-inden-5-yl)propan-1-one 
• 14927-64-1 3,5,6,7-tetrahydro-2H-s-indacen-1-one 
• 496-11-7 INDANE 

Relevant academic research and scientific papers

SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS

Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.

SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY

The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process. (I)

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.